Javelin Pharmaceuticals Inc (JAV)

[y3maxx]

<$10K profit today...
For those 3 or 4 Pro traders/Market Specialist who sold @100K shares this a.m. at $1.74/$1.75...to buy'em back at $1.66/$1.68.

...That's a lot of work for the reward.....its probably all computer driven.

So yesterday's same day drop and recovery does in fact look bullish confirmatory.

[y3maxx]

Bullish Close Tuesday

It was the first one day retracement/recovery in the eight months ive been long JAV.

[y3maxx]

Go to....

stockconsultant dot com

...1/2 way down the page click "chart movies"

...click "Breakout Patterns"

...scroll to last page

...Read #4

[y3maxx]

JAV...

1/
Why US market for dyloject bigger than EU

"Germany and UK basically account for 90 percent of sales of pain meds in EU. Germany has 80 million people and Uk 60 million. Initially this is only half the US population.
Secondly Uk has approx. 950 hospitals / Germany about 1500 - US has 5,906 hospitals as of 2007 - dont know the current figure.
Thirdly - the gold standard of post op is in the US. While the hospitals may form some kind of comp - America has HMO'S and PPO'S- PPO's allow doctors to perform out of offices and private pain clinics - AND those far outnumber anything in the EU.
In 2008 - the US had some astounding private clinic number - i want to say close to 70,000 but dont quote me.

Ketoralac and Morphine are standard pain injections in the US post op and emergency room. Dynastat from Pfizer did 300 million at it's peak, Paracoxib by Upjohn never made it to market was projected to take 30 percent share and do 400 million.

Emergency room visits in US outnumber EU 6.6 to 1.
Elective surgery (plastic and otherwise) US outnumbers
EU 4.5 to 1
Non-elective surgeries outnumber 3.4 to 1 "

http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_J/threadview?m=te&bn=72309&tid=62974&mid=62974&tof=26&frt=2#62974

2/
Dyloject revenue

Pacific Growth Equity's revenue projections for JAV

Javelin Pharmaceuticals - Dyloject Revenue Build in 1000's

2008 2009 2010 2011 2012 2013

Total Projected Dyloject Revenue $2,700 $16,686 $28,644 $131,335 $222,581 $303,778


starting 2011, thats when the US kicks in and you can see thats where the money is cause overall EU dyloject sales barely move over the 28,644 in 2011, 2012, or 2013

For example, in 2012, Total EU sales are $32,212, while US estimates in 2012 are $190,369.

in 2013 total EU sales estimates are $32,229 while US estimates are $271,538

If JAV even does 30% of these estimates, the stock is sickeningly undervalued, and it doesn't even take into effect Ereska sales

http://messages.finance.yahoo.com/Stocks_%28A_to_Z%29/Stocks_J/threadview?m=te&bn=72309&tid=62966&mid=62973&tof=27&frt=2#62973

[y3maxx]

Javelin Pharmaceuticals Completes Open Label Safety Study of Dyloject -

http://finance.yahoo.com/news/Javelin-Pharmaceuticals-bw-3034666400.html?x=0&.v=1

[y3maxx]

JAV Annual Shareholders Meeting June 23rd

1/
Voting for Directors

2/
Ratify appointment of public accounting firm

3/
Approve amendment to 2005 omnibus stock incentive plan
Increase the # to 11 million from 10 million shares

4/
Any other business

Question...

When do these 1 million new shares get "priced"?

[y3maxx]

JAV Update June 18th/09

Annual Shareholders Meeting...June 23rd

Ereska Ph 3 top line results...anytime

Dyloject Safety results...July (next month)

NDA submission...fall /09...could be sooner

[y3maxx]

ereska results will come on or after ASM...not before.

...Gotta price those 1 million JAV Management stock option shares as cheap as possible...don't you know.

Driscoll knows the street is waiting for Ereska results, so today's PR is actually a disappointment and will help keep the share price down until the Annual Shareholders Meeting on June 23rd.

[banna]

I expect positive results to be eventually released on Ereska. Because for years there has been a good bit of very positive research done on Ketamine for pain by Dr. Geo. D. Lundberg & others.
As for the pps of JAV , I have lived long enough to know that somebody ALWAYS knows something . And a small company like JAV is ripe for manipulation.

But in the end , when the FDA & manipulators are ready:

And when all the dust finally settles on Dyloject, I can reasonably see 100 - 150 million annual sales. And optimistiacally 150-200 million high end estimate.

Ereska, I reluctantly give the same estimates. Mostly because the potential use by the military is difficult to know.
Also , I see even bigger potential for somebody (not JAV) in selling ERESKA for "break through" pain & as pain treatment for cancer patients. Which is about a 2.5 billion dollar a year market now.

Which would suggest that if ERESKA took perhaps 10% of the cancer pain market , you could be looking at 250 million in annual sales from ERESKA alone.

Combining those estimates ,on the low end would suggest 200 - 300 million dollars in annual sales of both. And could suggest a potential JAV share price between 3.25 -5.00

The more optimistic estimates of 300-400 million, (which might could be made up by possible sales of ERESKA to the military), would suggest a Jav share price of 5 -6.50 . Which is close to WEDBUSH MORGANS target price of $6

It really seems to be just a matter of time.

[y3maxx]

If Ereska results come out negative then we know the shorters knew all along.

...But if Ereska results come out positive then one can surmise the weeks of trading leading to the Ereska PR have been purposely "mesmerizing", utilized to relieve Retail of their shares.

jmo

[y3maxx]

...Pincher Technical Analysis...

check out this board...

http://investorshub.advfn.com/boards/board.aspx?board_id=9737

Pinchers Technical Lesson (video)

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=37310639

SQNM, EROC were recent pinchers

[y3maxx]

...Three reasons why Ereska results delay is a coincidence....

1/

>>> Notice is hereby given that the Annual Meeting of Stockholders (the “Meeting”) of Javelin Pharmaceuticals, Inc., a Delaware corporation, will be held on Tuesday, June 23, 2009 at 9:30 a.m.,

.....3. Considering and voting upon a proposal to amend our 2005 Omnibus Stock Incentive Plan to increase the number of shares available for issuance thereunder from 10,000,000 to 11,000,000;<<<

http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0001206774%2D09%2D000915%2Etxt&FilePath=%5C2009%5C04%5C30%5C&CoName=JAVELIN+PHARMACEUTICALS%2C+INC&FormType=DEF+14A&RcvdDate=4%2F30%2F2009&pdf=

2/

>>>...on April 29, 2009, the Board determined to reduce the annual base salary of each of Mr. Driscoll and Dr. Carr from $450,000 to $300,000, which change shall be effective for the period from May 1, 2009 through April 30, 2010. In lieu of the foregone cash compensation, the Company granted to each of Mr. Driscoll and Dr. Carr on May 1, 2009 an aggregate of 104,167 deferred stock units (“DSUs”), which DSUs shall have an approximate aggregate face value as of May 1, 2009 equal to each executive’s total foregone cash compensation. The DSUs, each of which consists of one restricted share of the common stock, par value $0.001 per share, of the Company (“Common Stock”), will vest in twelve equal monthly installments beginning on June 1, 2009, and will be distributed in equal installments on May 1, 2010 and May 1, 2011. However, all DSUs will vest and be immediately distributed upon a change-in-control of the Company, and all vested DSUs will be immediately distributed upon a not-for-cause termination of either executive’s employment.

3/

...On April 29, 2009 the Board also approved an amendment to the cash bonus program for named executive officers for 2009 that was described in the Current Report on Form 8-K filed by the Company with the Securities and Exchange Commission on March 3, 2009. Specifically, in lieu of participating in the cash bonus program, Mr. Driscoll and Dr. Carr each elected to receive from the Company a grant of performance options to purchase up to 119,885 shares of Common Stock, which options were granted on May 1, 2009. These options will vest only upon the achievement of the Company’s corporate milestones for its cash bonus program, subject to accelerated vesting upon a change-in-control of the Company, and forfeiture of all of the options upon a not-for-cause termination of either executive’s employment.<<<

http://secfilings.nasdaq.com/filingFrameset.asp?FileName=0000930413%2D09%2D002450%2Etxt&FilePath=%5C2009%5C05%5C05%5C&CoName=JAVELIN+PHARMACEUTICALS%2C+INC&FormType=8%2DK&RcvdDate=5%2F5%2F2009&pdf=

[y3maxx]

ASM is June 23rd

[y3maxx]

20/50/200 M Avge's Converging...
http://stockcharts.com/h-sc/ui?s=JAV&p=D&b=5&g=0&id=p80295217854

[banna]

TORADOL annual sales are about $400 MIL ,as a generic & with its side effects. Dyloject ,has a patent (in EUROPE) & perhaps less side effects. When all this settles out could DYLOJECT potentially take 25%-50% of TORADOLS annual sales ?

Which suggests $100 -200 million annually from DYLOJECT alone.
What could ERESKA earrning potential be ?

Anyway ,just Say someone decides to buy JAV for about $3.50 a share or ABOUT $210 mil. They could perhaps make $100 -200 million a year off DYLOJECT till 2024 (supposing a U.S. patent of 2024 which is the European patent experation).

Over the life of the patent , DYLOJECT could make them perhaps about 1.2 -2.4 billion alone.

And what ever is made off of ERESKA would ju$t be extra gravy.

[banna]

Whats the potential earnings for ERESKA when all this settles out?

Going with the idea that ALL is good and slowly moving forward as expected. And going with the idea that the DOD might follow up their grants with actual implementation for battlefield usage or whatever.

For Dyloject , I have seen annual earning estimates for Dyloject at 75 mil in Europe & 175 mil in the U.S. Seems those figures were used to help come up with a price of JAV at around $500-600 mil.

I do not recall seeing any POTENTIAL earnings estimates for ERESKA.

Anybody ???

[y3maxx]

>JAV still trading @ 30% below the American Bio Tech Index.<

...year over year that is...

[y3maxx]

JAV still trading @ 30% below the American Bio Tech Index.

[Cee-It]

JAV needs to stay above that 50 MA tomorrow and then it could start kicking the BB to a more sustained upward trend.

[y3maxx]

JAV/$BTK Comparable Chart...

http://stockcharts.com/charts/performance/perf.html?JAV,$btk

[hptaxis]

Ketamine – Abuse v Use


'Special K' Goes Global

http://www.huffingtonpost.com/2009/05/22/special-k-goes-global_n_206829.html

By Ginanne Brownell -- Special to GlobalPost
05-22-09

LONDON -- In Europe and North America it's called a k-hole. In Asia it's been dubbed a k-ride. Semantics aside, for many users the hallugenic immobile state that comes from taking a lot of ketamine -- which can be snorted, injected or swallowed in pill form -- is exactly the reason they use the drug.

For others it's a bizarre and frightening experience and is the reason why "K" is called the Marmite of drugs -- you either love it or hate it. In recent years, enough users have loved it that the use of ketamine, commonly used as a horse tranquilizer, is spreading beyond the club scene.

Ben, a 30-year-old university student in London, says he has taken the drug about 20 times in the last few years. Usually he snorts just a small "bump" at clubs, which makes him feel warm and puts a surreal tint on everything. But on two occasions he took too much and entered into a k-hole -- which users describe as a psychedelic out-of-body or near death experience -- and it left him freaked out.

"The first time I knew I had taken too much because everything kind of went into 3D like I was in 'The Matrix,'" he recalls. "My friends were having to hold me up as I was walking along and though I knew my feet were touching the ground it felt like they were 10 steps behind me; I felt like my consciousness was separate from my body and I was floating."
For a long time after that, Ben was careful about the amount he took. But last summer at the Glastonbury Festival, he accidentally took too much again. "I was watching the Chemical Brothers on stage when everything just pixilated and I remember falling into people behind me -- I was a mess."

The mess that is ketamine abuse is becoming a serious problem across the globe.
A 2008 report from the United Nations Office on Drugs and Crime (UNODC) found significantly increased use reported in Asia, Europe and North America. Several countries -- including Britain, the U.S., China and New Zealand -- have made the anesthetic illegal to possess without a license or prescription.

Asia has a particularly serious problem with K -- it is the primary drug of choice in Hong Kong, it ranks as the second leading drug abused in Singapore and the fifth in China.

Europe also is seeing a problematic increase. A 2007 report from the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) found that regular use of GHB and ketamine among clubbers -- the genre where K first became popular -- ranged from 6.7 percent in the Czech Republic to almost 21 percent in Hungary. In Britain the number has grown from an estimated 65,000 users in 2000 to 90,000 in 2007 with the numbers of users increasing by 10 percent last year.

Experts point to several reasons why ketamine use is on the rise. First, K is significantly cheaper than other drugs: In Britain the price has dropped from 30 pounds a gram -- roughly $45 -- to about 10 pounds a gram, while in Hong Kong a dose costs the same as a pack of cigarettes.

And unlike more traditional hallucinogens like LSD, ketamine's chemical ingredients are fairly easily ordered off the Internet. There is also the misconception that K is safer than other drugs, although recent research in places like Hong Kong, Britain and Canada has shown that extended abuse can lead to severe bladder and kidney problems.

"What we know is that it is taking off in Britain, in North America in certain pockets, in parts of Asia like Thailand where people are seeking it out as their drug of choice, and in the Philippines where there has been production and use of it," said the UNODC's Jeremy Douglas. "So we are seeing increased use worldwide, but it is hard to measure because it is not illegal in some jurisdictions."

First developed by Parke-Davis in the early 1960s as a surgical anesthetic, ketamine was used by mobile surgical units during the Vietnam War because it knocked people out quickly. After complaints that the anesthetic caused hallucinations and strange nightmares, ketamine fell out of favor in Europe and North America (though it is still used in surgery across the developing world because it is cheaper than other anesthetics). It is most commonly used today as a horse tranquilizer.

With the rise of clubbing and the drug Ecstasy across the globe in the 1990s, ketamine also began appearing on the dance scene. European DJs were introduced to K at beach parties in Goa, India -- where the drug can be purchased over the counter -- and started bringing it back home.

"K was first associated with the gay clubbing scene and so it started with that group and then filtered out from there," said Karenza Moore, a lecturer in criminology at Britain's Lancaster University who has done extensive research on ketamine and the clubbing scene. "In Britain it seems to be popular with older clubbers -- maybe it was the maturity of the scene with people wanting new experiences -- so that is where K came in and it has gone from something that no one did to something that is always there if you want it."
Worryingly, K seems to be moving from just a clubbing drug to more mainstream use in certain pockets of the globe.

"Students as young as 17 are becoming heavily involved in the drug," said Pete Weinstock, who works for the British-based Bristol Drug Project charity. "It is now being used in so many different places like pubs and parks -- where it used to be confined to one or two settings."

Matthew Southwell, a former drug user who now looks at emerging drug trends in Britain, said there is a concern that young kids are using ketamine in heavy doses. "We are seeing kids who who chose to buy grams of ketamine to get f***d up because its cheaper than alcohol," he said. "These are not young clubbers -- these are kids bored out of their minds and it has much more in common with binge drinking than club culture."

In Hong Kong, where the number of drug users under 21 who used K jumped from 1 percent in 1999 to 73 percent in 2006, the drug is so prevalent that teenagers have been arrested for possessing and using K in schools. One 14-year-old girl, who developed serious bladder problems due to sustained use, had been using the drug since she was 10.

"The drug was in the clubs and then it moved to the student population," said Douglas. "In Hong Kong K became cool because it was different -- the success of illicit drugs depends on the marketing campaign -- and in Hong Kong that campaign [has proved] very successful."

[banna]

Insiders have bought lots of JAV at $2.50 -$3.50 a share over the years.
Millions of Jav shares were purchased by some of the various capital players at $ $3+ a share.
In one of the instances is seems that 50,000 shares were excercised at $4.19 a share.

I have no crystal ball for the future. Just seems like any deal that brings only $2.00 -$3.00 a share could only be a break even point for many of the larger long term investors considering their overall stock cost basis.

Also just can not help but be impressed with the credentials & contacts that the JAV board of directors have. Their contacts span from Schering-Plough to the FDA,etc, so they seem to be very well connected.

So it would seem that if there is a way to get more than $2-3 a share, these guys & gals have a real financial incentive to do so.

[y3maxx]

JAV could be "pinching".....

http://stockcharts.com/h-sc/ui?s=JAV&p=D&b=5&g=0&id=p44450499034

[Cee-It]

Wait for it... this is going to fly high soon. Summer tradding may hold it back for awhile, but this is a great price level for increasing holdings.

[y3maxx]

We are still trading lower than May 7th Q results.

[banna]

Casino JAV ...Place your bets... lose big or win big ! I am betting on a buyout. Because:
(1)Hospitals can cut cost with Dyloject.
(2)DOD seems to want Ereska badly to help save troops lives.
(3)JAV management & directors stock ownership keeps increasing.
(4)Seems lots of effort & manipulation is going on to keep the share price down.

Seems lots of people will win big if JAV succeds & was to get bought out.

[y3maxx]

aka: Casino JAV

eom

[banna]

y3maxx, read your post for months & have followed your advise about the YMB & came here for some actual JAV discussion.

I first got into JAV in OCT 08 , and also see lots of potential in JAV. I am looking for a buyout between 6 -10 a share ( value JAV at 360 - 600 million). Also see the management taking some stock instead of all cash as a positive . Especially the directors, (have you researched some of the conections of the directors)?
Anyway, Am looking forward to seeing whether the short interest data reveals some serious short covering or not. Serious short covering would seem to be a very bullish signal to me.
And as always I expect that there could be some active manipulation of JAV share price . My opinion is that it seems that the share price has been worked down intentionally for a purpose.

[y3maxx]

...Blatant Market Specialist Trading...

...Retail had two opps since Dec for decent trades.

the day it hit 40 cents and the $1.00 to /$1.50 month long trend.

The Hedgefund/Market Specialist is otherwise controlling every trading day since.

...Should we get positive Ereska news, retail will get another great trading opp....plus the daily Beta will also return as we will have much larger daily volume.

good luck

[y3maxx]

Ereska results coming soon.

...Market Specialist is hard at work.

[y3maxx]

JAV...Two germane snippets from YMB

.....It is otherwise a useless message board....


>>I'm not saying there will be an immediate groundswell of use, but there clearly will be a niche for this drug- none of us know how much of a niche without a crystal ball and proper marketing by a big pharma. Remember, there is no other IV NSAID available- so any alternative with a better safety profile will find a niche.<<


>>they didn't even try to sell dyloject, sport..All they were trying to do was get the drug on the hospital formularies, which of course they did.. it wouldnt have mattered if JAV had a cure for cancer, some jackleg drug reps they pulled off the street couldn't sell it.

if Dyloject wasn't a great drug, Therabel wouldnt have partnered up with them.

There's a hedge fund that owns 4 million shares of JAV that spent 100k on independent US dyloject research before they loaded up. thats right, $100,000. and when it got at 50 cents, they bought 2.5 million additional shares. They only had 1.5 million before that.<<<

-------------

1/
Dyloject...2 ph 3's already reported..Safety trial results in July

Ereska....top line ph 3 results expected anytime

2/
New CEO as of March/08....CC ten days ago said No share dilution...Management also swapped $100K salary for stock options two weeks ago.. I believe it is bullish...$200 or $300K of salary vs. $18 million cash on hand...no debt

...We shall see...

do your dd

[y3maxx]

JAV...Sunday, May 10, 2009
Best Stocks For 2009 From America's Leading Advisors

Best Stocks 2009 No.4 How One Tiny Drug Developer Could Take Down The Industry Leaders
by Greg Guenthner

>>>Grab Your Share of a $31 Billion Market In 2007, the global pharmaceutical pain relief market was worth approximately $31 billion.

In the U.S., two-thirds of the dollar volume of the prescription pain medication market is for drugs used to treat chronic pain, with the remainder going toward drugs used for acute pain.
Javelin Pharmaceuticals Inc. (JAV: AMEX) designs products to fulfill unmet and underserved medical needs in the pain-management niche............<<<

http://markets-strategy.blogspot.com/2009/05/best-stocks-for-2009-from-americas.html

[y3maxx]

Therabel Pharma

....Dyloject Europe was sacrificed...

1/
in order to eliminate overhead as cash burn would take JAV into BK before Ereska ph3 and Dyloject Safety results.

The alternative was share dilution and the CEO stated..."No share dilution".

2/
We shall see if the previous seven trading days were short covering.

3/
Management's swap of salary for stock options underlines JAV's potential upside....hoping Gabe's #'s are conservative.

[y3maxx]

JAV Last four days...
have been classic professional short covering...

...Ereska ph 3 results expected in a few weeks...

Javelin Pharmaceuticals, Inc.Amex
Settlement Date Short Interest Avg Daily Share Volume Days To Cover
4/30/2009 1,979,281 127,566 15.515741
4/15/2009 2,029,618 120,996 16.774257
3/31/2009 2,192,950 201,607 10.877350

..I remember @ 3 years ago when JAV was on the list of potential 5 baggers...and it was at $5 a share then.

JAV has seen some share dilution, now 62 million OS,
however the less than 2 year CEO has decreed..no more share dilution.

Last week management swapped salary for stock options.

...When was the last time you saw that...

[acgood]

I'm afraid 1.01 was the low, I was trying to grab some at 0.95.

[y3maxx]

The 2 million short position has been covered

these last four days....just cleaning up their position.

...Gabe has no clue.

They took'em right out of Retail's pockets.

[y3maxx]

Last four days have seen...

@1.5 million shares stolen, i mean traded from Retail investors.

Hold your shares.

[alfabeta]

It will take 2-6 weeks, right? Since they have been preparing for that letter for months, I guess they will finish it in less than 3 weeks. After then, on July we will finish dyloject safety trial. Why did they believe dyloject filing will be first and ereska second?

[y3maxx]

JAV...Share price = Ereska ph 3 failure?....


""There's no possible way anyone knows if Ereska worked or not. Not til they unblind the data. But just remember, Ketamine has been used to treat pain successfully for 30 years and showed stellar results in phase 1 and phase 2 trials.

Here's some Ereska background

Previous randomized, double-blinded, placebo-controlled phase II clinical studies have demonstrated statistically significant (p<0.05) relief of moderate to severe post-operative and breakthrough pain. Ereska was fast-acting, with statistically significant (p<0.05) pain relief occurring as early as 4 minutes post administration of Ereska. Ereska also appeared to be safe and well-tolerated by patients. These results were presented at the American Society for Clinical Pharmacology and Therapeutics in Atlanta, Georgia in April 2002 and the American Society of Clinical Oncology in Orlando, Florida in May 2002. In May 2003, following the presentation of clinical data at the plenary session of the Advanced Technology Application for Combat Casualty Care conference in Orlando, Florida, the U.S. Department of Defense awarded a $4 million funding extension to Javelin to aid in the development of Ereska. This award is based on the need of the military for a fast-acting, non-invasive, and non-sedating alternative to the intravenous and oral medications commonly used for treatment of combat-related injuries. In June 2004, the company attended the End-of-Phase II meeting with representatives of the U.S. Food and Drug Administration (FDA). In August 2005, Javelin presented a meta-analysis of three randomized, placebo-controlled studies involving ketamine analgesia for patients with acute moderate-to-severe pain. The results of the meta-analysis demonstrated that intranasal ketamine was effective at relieving moderate-to-severe pain over the 10 to 50 mg dose range with no statistically significant changes to vital signs or arterial oxygen saturation levels. These data were presented at the Department of Defense’s premier medical conference, the Advanced Technology Application for Combat Casualty Care in St. Petersburg, Florida""

gbass

[y3maxx]

From:... myself...
Sent: Wednesday, May 13, 2009 9:53 AM
To: Driscoll, Martin
Subject: re: Jan 15th/09 Press Release...



Dear Mr. Driscoll,



...I remain a JAV shareholder and I appreciate your own $$$ commitment and vision as a JAV shareholder as well as being JAV's key leader.



We await Ereska top line results.



...FYI, it seems JAV's Market Specialist utilized a delayed Press Release to their advantage for nearly 15 minutes after that morning's market open.



yours truly,

xxx


Response from CEO Driscoll...

Dear Mr. xxx,



Thank you for your support. Now that we have the FDA comments on our Statistical Analysis Plan (SAP) for our Ereska pivotal trial, we are moving forward to do all the work necessary to lock the trial database. Unfortunately, we could not conduct this work until we received the comments.



Our Market Specialist continually frustrates us.



Best regards,



MD



Martin Driscoll

Chief Executive Officer

Javelin Pharmaceuticals, Inc.


--------------------------------------------------------------------------------

[y3maxx]

Justice to those who sold and saved 20 or 25 cents, but did not buy back at current levels, would be to have an offer to buy out JAV appear tomorrow a.m.

[y3maxx]

The January Partnership w/ Therabel Pharma N.V.

That tells me JAV is for Sale and will be sold, will not become a shell simply to collect royalties...That prospect is too far off and patents last only for so long and new better drugs are always a possibility.

CEO Drsicoll has only been with JAV for 15 months and imo, he has done everythinhg right to this point.

Sale price, within one year....depending on the Ereska and Dyloject successes...

$1.00 to $10.00.

[y3maxx]

What is the difference between...
this stock swap for salary vs a straight out purchase of 80K of shares by mgmnt?

[y3maxx]

...Retail talked themselves out of 1 million shares...
last two days.

...Those million shares expected dyloject & Ereska results.

1/When they didn't come,

2/FDA responded two days ago, but retail didn't buy it,

3/retail figured that two $100K salaries swap for stock wasn't bullish vs $18 million on hand in cash, no debt.

[y3maxx]

By waiting for and including Dyloject's Safety trial results will make the European approval a no brainer.

[y3maxx]

JAV, Received Customary FDA Response/Comments Yesterday

for ph 3 Ereska trial...strictly an FDA administrative delay

...will take a short time to unblind ph 3

Dyloject NDA on track for 3rd or 4th Q

Cash will support JAV into 1st Q /10

...CC ongoing...

[y3maxx]

Quarter Results out.... includes deficit of ($168,694,602.00 )

CC at 8.30 am....no guidance re: Dyloject or Ereska/FDA in PR.

They have listed JAV's NOLS...

Deficit accumulated during the development stage ($168,694,602.00)

...At this point I take it JAV is For Sale.

[y3maxx]

Likely results tomorrow are...

Dyloject sales moving forward slowly,

...Ereska top line results delayed due to FDA

Management's stock option swap for income is a positive, results will show within a year.

good luck to all longs

[acgood]

how would that not be the equivalent of insider trading if they already have seen the data?

[y3maxx]

<>>why would you cut your own salary ahead of sucessful ereska data or a new partnership??<<<


1/

If bad company news was coming, management would prefer $$$ pay raises vs questionable stock options?

And if good news was coming one would prefer stock options vs cash.